Ocata does have a Wiki page, of course, but it needed a little updating. There’s a LOT that could potentially be added because so much exciting stuff has happened recently, and today I added the news about the official completion of Phase I/II and the EMA pivotal trial designation. There’s still a lot that could be done, but I’m really glad that the page exists in the first place. Go and take a look!
Here’s the Ocata page.
Here’s a cogent, intelligent, and rational comment to the news below:
3458qu9fqu4589q3u-!!!!! OMG I DON’T EVEN. O.o.
This moment has been brought to you by the Department of Medical Miracles to Come. 🙂
THIS IS WHAT WE’VE BEEN WAITING FOR!!! It’s the OFFICIAL announcement! Ocata can now start the second trial! They have pivotal trial status from the European Medicines Agency! This means that they can start marketing the drug after the next trial is over! It would be the FIRST stem cell based drug approved since 1956! Yes, I really DO think that we need all of these exclamation points!!!
Capslock? What capslock? 😉
Ahem. Anyway, check it out. 🙂
Ocata’s Press Release on the Completion of Phase I/II of SMD Trials
So… we’re done with the raw notes for now, and we’re back to the writing! Believe me, you do NOT want to miss the info in today’s installment. If you’ve ever wondered whether or not you should keep your investments in a certain biotech company, for instance… the answer’s here. Enjoy!
Posted in Stem cell ethics
Tagged adult stem cells, Alison Sorkin, cure for blindness, embryonic stem cells, induced pluripotent stem cells, ipsc, japan, nanette joyce, ocata, paul knoepfler, right to try, takahashi, uc davis, yamanaka
At the end of part one, Tim Caulfield, keynote speaker at the conference, was addressing the problem of illegal stem cell clinics worldwide…
Tim Caulfield looked up. “So what’s the harm?” he asked.
I wasn’t sure if anyone in the audience was supposed to answer the question, but I did not have a good feeling about whatever was coming next.
Posted in Uncategorized
Tagged cures, dickey wicker, embryonic stem cells, FDA buyers' club, geron, hype, Neuralstem, ocata, oklahoma, paul knoepfler, regenerative medicine, right to try law, shirley vs sebelius, stem cells, tim caulfield
So I just finished Dancing With a Stranger, by Meryl Comer, and… it’s not exactly the feel-good book of the year. She is a caregiver for BOTH her husband AND her mother, and both have Alzheimer’s. Oh, yeah– and she has both of the genes associated with the disease. Just the fact that some people are able to keep going in the face of unbearable problems is hard to believe.
I’ve been looking into the current state of stem cell based AD trials, and here’s what I’ve found out. As of December 2014, there’s not a lot going on at the clinical level right now. There’s one trial in South Korea using cord blood-derived cells, but even though they completed the preliminary outpoint in 2012, there does not seem to have been any information released on what the outcome was, which isn’t very encouraging to me. Dr. Lanza’s article about preliminary interim results in Ocata’s RPE trials for AMD was released months into the study. So, for it to be fully two years after the completion of Phase I, and still nothing… not that great. Another study in China is now recruiting, but I’m not sure how much better that one looks.
There are a few meds in development that look promising… but the problem with drug trials is that there’s a long history of meds looking great for AD until they’re actually released, and then they turn out to not accomplish much of anything over the long term. I’ve seen a couple of drugs really help people in the early stages, but only for about one year (Aricept and Namenda are good examples.)
The most promising thing I’ve seen, IMHO, is Neuralstem’s animal studies on Alzheimer’s. They released results in October, and the conclusion is that their cells “rescued spatial learning and memory deficits in mice with an animal model of Alzheimer’s disease.” The problem obviously is that we’re only talking about mice at this point, and there is, unfortunately, a history of stem cell treatments looking wonderful in mice and then not translating to humans. Still, if I had more money, I would definitely invest in this company!
So that’s pretty much the AD story for now!
Posted in Alzheimer's
Tagged Alzheimer's, aricept, caregiver, cord blood, dancing with a stranger, investigational drugs, memory, memory problems, meryl comer, namenda, Neuralstem, ocata, regenerative medicine, robert lanza, stem cell
So today was the wrap party for NaNo (National Novel Writing Month,) and I read from the stem cell book I worked on all through November. (Yep, it’s the planned book on this site, And the Blind Shall See: The Promise of Stem Cell Cures.) It came from the section on working in hospice with Alzheimer’s patients. People were really touched (and I’m not going to try to claim that it was from the amazing writing quality!) No, it’s because everyone can relate to the desperate need for cures for degenerative diseases. And yet it’s basically a situation where even the most educated people never know almost anything about what’s really going on with truly effective stem cell research (like Ocata’s.) If you’ve ever lived with the situation of caring for a relative who has a degenerative disease like Alzheimer’s, you know how utterly draining it is, how much it takes out of you. I saw it every single day when I worked hospice. And it isn’t just older people, believe me. There was one woman I knew who died of MS when she was only thirty-six years old. I’m going to put up a series of posts on working with patients who had degenerative diseases, and there’s quite a range of those. Alzheimer’s, other types of dementia, MS, COPD, severe arthritis, and on and on and on. These might not be the most cheerful stories in the world– but we’re working on a happy ending through regenerative medicine! 🙂
Posted in The diseases stem cells could cure
Tagged Alzheimer's, arthritis, coping, cures, dementia, embryonic stem cells, hope for terminally ill, hospice, multiple sclerosis, ocata, patients, regenerative medicine
So, I was posting a summary for my book on the NaNoWriMo Facebook page, thinking that it sounded over the top… stem cell-based cures for horrible incurable diseases within 2-10 years, that kind of thing… well….
There’s no link for this, because it is insider info from shareholders who went to Ocata’s quarterly meeting in Boston, which was not open to the public. (There is a LOT about Ocata in the book– they’re the biotech company that just changed their name from Advanced Cell Technology.) Ocata is the company developing the first cure (or even treatment!) for age-related macular degeneration, a disease that slowly causes blindness for 30 million people in the U.S. and Europe alone. The interim published results for the clinical trials have looked great, but as far as when this treatment might actually come to market… it’s everybody’s guess.
But in the quarterly meeting… several attendees have all said the same thing. The drug already has orphan treatment approval for a genetic disease caused Stargardt’s, which has exactly the same effects and eventually causes blindness. But it attacks much younger people, including children as young as six. (Yep, six years old.) AND… the CEO of Ocata said that the drug will be available in the U.K. in 2018. We don’t have absolute confirmation of this yet. But it’s apparently what was officially said at that meeting.
One of the lines of thought on the forums is that the date might be earlier for AMD approval in the U.S, even quite a bit earlier if the drug is fast tracked here… we just don’t know. But this is INCREDIBLE!!!~ There has never ever been any kind of treatment for Stargardt’s before, and now there will be, and it will be STEM CELL BASED. As of now, that will be the first drug approved anywhere in the WORLD that is embryonic stem cell based.
YES! IT’S THE START OF A NEW ERA IN MEDICINE!!! And it will be in the book!
(sorry about the capslock…
Posted in Great News
Tagged advanced cell technology, amd, cure for blindness, cures, embryonic stem cells, investigational drugs, miracles, ocata, robert lanza, stargardt, stargardt's, stem cell, stem cells, treatments, trials
Stem cells. The hope, the hype; the successes, the failures; the frauds, the triumphs, and the miracles in the making. It’s all going to be here! Oh, okay; ALL of the information in the world about stem cells is probably NOT going to be found here. 😉 But if I can find it out… will be. There will be much more content here, including the story of just why and how I became so passionate about the entire issue of stem cells and regenerative medicine. I can honestly say that some of what you’ll read here is unique and cannot be found anywhere else the world. So just keep watching this space– some incredible things are coming up!